CALL/VERTEX PHARMACEUTICALS/350/0.1/17.01.25 | Real-time BOERSE MUENCHEN 04:26:47 2024-06-21 am EDT | ||
| 12.8 EUR | +0.63% |
|
| Current month | +16.70% | ||
| 1 month | +19.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 12.8 | +0.63% |
| 24-06-20 | 12.72 | +3.33% |
| 24-06-19 | 12.31 | -2.30% |
| 24-06-18 | 12.6 | -6.32% |
| 24-06-17 | 13.45 | -2.11% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 04:26 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP4M1R |
| ISIN | DE000GP4M1R3 |
| Date issued | 2023-05-10 |
| Strike | 350 $ |
| Maturity | 2025-01-17 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 6.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.97 € |
|---|---|
| Lowest since issue | 4.82 € |
| Spread | 0.3 € |
| Spread % | 2.28% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Warrants
- Warrant
